Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, dedicated to the discovery and development of small molecule therapies that harness the body’s innate protein disposal machinery to selectively degrade disease-causing proteins. Founded in 2016, Kymera employs its proprietary Pegasus™ targeted protein degradation platform to discover novel small molecules that address diseases with high unmet medical need, including immune-inflammatory disorders and oncology indications.
At the core of Kymera’s business is its Pegasus™ platform, which integrates expertise in medicinal chemistry, structural biology, and proteomics to design molecular glue degraders and protacs that drive ubiquitination and degradation of specified protein targets. The company has advanced multiple development candidates into the clinic, focusing on programs such as IRAK4 degraders for autoimmune diseases and IRAK1/4 inhibitors for both inflammation and cancer. Kymera also maintains a robust discovery pipeline with research collaborations and internal efforts targeting transcription factors and other traditionally “undruggable” proteins.
Kymera’s research and clinical programs are supported by a network of trial sites and research collaborations across North America and Europe. The company has entered strategic partnerships with leading pharmaceutical organizations to expand its capabilities and accelerate the development of its product candidates. These collaborations extend Kymera’s reach, allowing it to leverage external expertise in immunology, oncology, and translational medicine to validate new therapeutic approaches and broaden its pipeline.
Under the leadership of President and Chief Executive Officer Nello Mainolfi, Kymera has built a multidisciplinary team of scientists, clinicians, and industry veterans dedicated to advancing the field of targeted protein degradation. The company’s leadership team includes experts in drug discovery, clinical development, and regulatory affairs who guide Kymera’s efforts to translate scientific innovation into transformative therapies. Kymera continues to invest in its platform technology and strategic partnerships with the goal of bringing first-in-class or best-in-class treatments to patients worldwide.
AI Generated. May Contain Errors.
